ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TSX: CTX June 13, 2018 — Laval, Québec
FORWARD-LOOKING STATEMENTS Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning of applicable securities laws, including, among others, statements concerning the Company’s objectives and strategies to achieve those objectives, sales of the Company’s products, the Company’s product candidates and the timeline for their development and commercialization, the Company’s future financial condition and performance, potential acquisition and licensing transactions, as well as other statements with respect to management’s beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Such forward-looking information reflect management’s current beliefs as of the date hereof and are based on information currently available to Management. Although the forward-looking information contained in these materials and to be discussed during this presentation is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking information is based on the Company’s estimates and assumptions, and is subject to risks and uncertainties, that could cause actual results to differ materially from such forward-looking information, including those described in the Company’s annual information form, management discussion and analysis and other documents filed with Canadian securities regulators, copies of which are available under the Company’s profile at www.sedar.com. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. 2
Daniel N. Chicoine Executive Chairman of the Board 3
Serge Verreault Jose DaRocha President and Chief Chief Financial Officer Executive Officer 4
AGENDA 1 Approval of the 2017 audited consolidated financial statements 2 Election of directors 3 Appointment of auditors 4 Approval of advance notice provisions for the election of directors 5 Approval of share incentive plan 5
1 Fiscal 2017 Annual Report and Financial Statements 6
2 Election of the Board of Directors 7
ELECTION OF THE BOARD OF DIRECTORS David A. John C. Samira Daniel N. Anthony E. Thomas Copeland Dobranowski London Sakhia Schlader Chicoine 8
3 Appointment of auditors 9
4 Approval of advance notice provisions for the election of directors 10
5 Approval of share incentive plan 11
MANAGEMENT PRESENTATION
Serge Verreault President & CEO Remarks 13
DELIVERING TO ALL STAKEHOLDERS Building trust VISION To be a leader in innovative science-based People skincare, providing improved outcomes for all of our clients’ skincare concerns MISSION To provide accessible science-based skincare Customers Shareholders solutions through innovation in order to enhance skin health and the overall wellness of our consumers 14
CRESCITA AT A GLANCE CRESCITA is a Canadian commercial dermatology company serving the prescription (Rx) & non-prescription (non-Rx) markets 2 patented technologies Strong pipeline of RX is distributed by and 250+ proprietary product candidates and Taro Pharmaceuticals Inc. in the formulations cosmeceuticals U.S. and by Galderma in ROW 50,000 sqf manufacturing 3 established facility in Montreal offering Strong sector-specific management team skincare brands Contract Manufacturing Services and R&D capabilities 15
SALES & DISTRIBUTION FOOTPRINT Non-Rx brand portfolio 16
PROPRIETARY TECHNOLOGY PLATFORMS Topical and Transdermal Drug Delivery MMPE™ Peel & DuraPeel ™ Multiplexed Molecular Phase-Changing Penetration Enhancer Topical Cream Combinations of FDA approved excipients Phase-changing cream using self-occlusion deliver actives into or through the skin to deliver actives into or through the skin Both technologies can be used for Rx and non-Rx products 17
RX PRODUCT The only FDA-approved, phase-changing, • Topical local anaesthetic that provides safe and effective local dermal self-occluding topical Description analgesia on intact skin anesthetic cream with the highest • • API / Indication 7% Tetracaine + 7% Lidocaine Pain concentration of Flexicaine, 2 nd generation until 2031 • • Patent Status Tetracaine and Pliaglis until 2020 Lidocaine • • Dermal filler injections Laser-assisted tattoo removal Used for • • Pulsed-dye laser therapy Non-ablative laser facial resurfacing • Exclusive licensing agreement with Taro for U.S. rights signed in 2017 • Commercial Pliaglis launched in U.S. in Q1-18 Status • Galderma has ROW distribution rights. Crescita can reacquire starting in 2021 • Potential for a further US$5.25 million in milestones 18
DRIVING TRANSFORMATION 2019 & Beyond 2018 Pursue transformational operational and business 2017 cont’d development activities Raised $3.5M through Rights offering 2017 Acquired of the Alyria Announced U.S. launch product line of Pliaglis Out-licensed Pliaglis U.S. Amended Knight loan Announced first-time rights to Taro freeing up $6.0M in cash ever positive EBITDA Advanced Rx product Completed $1.0M Serge Verreault pipeline and reported convertible debenture named CEO positive Phase 2 Results financing for MiCal 1 Paid down long-term debt Defined and of $4.2M implemented 4-pillar growth strategy 19
CORPORATE STRATEGY & FOCUS Strategic Acquisitions & Organic Growth In Licensing Agreements Operational Effectiveness – Innovation & Technology International Contract Markets & Manufacturing Out-Licensing Services (CMO) Agreements 20
GEARED FOR GROWTH Rx Milestone Opportunities MiCal 1 – Potential Significant Pliaglis Pliaglis re-launch milestones and out-licensing launch in Canada in U.S. market royalties potential upfront payment by Taro from Pliaglis continue Milestone – U.S. FDA Approval of Received 1 st Royalty “Not for Home Use” Regulatory payment of $1.4M from label Restriction approval of U.S. sales of Pliaglis removal Flexicaine 2018 2019 Focused on organic growth, strategic LM&A, international market expansion and CMO - ONGOING 21
IMPROVING REVENUE & EBITDA *Adjusted EBITDA is a non-IFRS measure. This term is defined as earnings (loss) from continuing operations before interest, income taxes (recovery), depreciation and amortization, gain on debt renegotiations, net, equity-settled stock- based compensation (“SBC”), 22 goodwill and intangible assets impairment, accretion on the fair value of inventory, and foreign currency (gains) and losses.
MARKET CAPITALIZATION and Share Price $17.2M $0.82 $9.5M $9.1M $8.8M $0.45 $0.65 $7.7M $0.62 $0.55 Q3-17 Q1-18 Q2-17 Q4-17 June 12 23
OUR STRATEGIC TARGET Strategic Aspiration to be a profitable $50M revenue-generating commercial dermatology company in 5 years 2018 2020 2023 24
PROXY VOTE COUNT RESULTS
PROXY VOTE COUNT Election of Directors Elect Directors For % Withheld % ▪ Daniel N. Chicoine 91.0% 9.0% ▪ David A. Copeland 91.2% 8.8% ▪ Anthony E. Dobranowski 91.0% 9.0% ▪ John C. London 91.0% 9.0% ▪ Samira Sakhia 91.2% 8.8% ▪ Thomas Schlader 91.2% 8.8% 26
PROXY VOTE COUNT Appointment of Auditors For % Withheld % ▪ Appointment of Ernst & Young 91.4% 8.6% as auditors 27
PROXY VOTE COUNT Amendment to By-Law Number 1 For % Withheld % ▪ Approval of Amendment to 91.0% 9.0% By-Law Number 1 28
PROXY VOTE COUNT Approval of Share Incentive Plan For % Withheld % ▪ Approval of share incentive plan 84.4% 15.6% 29
THANK YOU ANY QUESTIONS?
Recommend
More recommend
